TY - JOUR
T1 - Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes
AU - Philis-Tsimikas, Athena
AU - Aroda, Vanita R.
AU - De Block, Christophe
AU - Billings, Liana K.
AU - Liebl, Andreas
AU - Sivarathinasami, Ramsathish
AU - D’Cruz, John M.
AU - Lingvay, Ildiko
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Novo Nordisk A/S.
Publisher Copyright:
© 2023 Diabetes Technology Society.
PY - 2023
Y1 - 2023
N2 - Background: Derived time in range (dTIR), calculated from self-monitored blood glucose (SMBG-dTIR) profiles, has demonstrated correlation with risk of cardiovascular and microvascular complications. This post hoc analysis of the DUAL V and DUAL VIII trials aimed to compare dTIR with an insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus insulin glargine 100 units/mL (glargine U100) in people with type 2 diabetes (T2D). Materials and Methods: Nine-point SMBG profiles were taken more than 24 hours at baseline and end of trial (EOT: 26 weeks [DUAL V] and 104 weeks [DUAL VIII]) and used to derive the percentage of readings within target range (70-180 mg/dL). Estimated treatment differences (ETDs, IDegLira–glargine U100) were analyzed using analysis of covariance, with treatment as fixed effects and baseline response as a covariate. Results: ETDs for change from baseline to EOT in dTIR were significantly greater with IDegLira versus glargine U100 in DUAL V (4.18%, P =.027) and DUAL VIII (5.17%, P =.001). The proportions of people achieving ≥70% dTIR at EOT with IDegLira and glargine U100, respectively, were 62% and 60% in DUAL V (P =.7541), and 50% and 26% in DUAL VIII (P <.0001). The proportion achieving a ≥5% increase in dTIR from baseline to EOT with IDegLira and glargine U100 was 63% in both groups in DUAL V (P =.9043), and 44% and 25%, respectively, in DUAL VIII (P <.0001). Conclusions: IDegLira was associated with significantly greater increases in dTIR versus basal insulin alone in people with T2D. Trial ID(s): ClinicalTrials.gov, NCT01952145 (DUAL V); ClinicalTrials.gov,
AB - Background: Derived time in range (dTIR), calculated from self-monitored blood glucose (SMBG-dTIR) profiles, has demonstrated correlation with risk of cardiovascular and microvascular complications. This post hoc analysis of the DUAL V and DUAL VIII trials aimed to compare dTIR with an insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus insulin glargine 100 units/mL (glargine U100) in people with type 2 diabetes (T2D). Materials and Methods: Nine-point SMBG profiles were taken more than 24 hours at baseline and end of trial (EOT: 26 weeks [DUAL V] and 104 weeks [DUAL VIII]) and used to derive the percentage of readings within target range (70-180 mg/dL). Estimated treatment differences (ETDs, IDegLira–glargine U100) were analyzed using analysis of covariance, with treatment as fixed effects and baseline response as a covariate. Results: ETDs for change from baseline to EOT in dTIR were significantly greater with IDegLira versus glargine U100 in DUAL V (4.18%, P =.027) and DUAL VIII (5.17%, P =.001). The proportions of people achieving ≥70% dTIR at EOT with IDegLira and glargine U100, respectively, were 62% and 60% in DUAL V (P =.7541), and 50% and 26% in DUAL VIII (P <.0001). The proportion achieving a ≥5% increase in dTIR from baseline to EOT with IDegLira and glargine U100 was 63% in both groups in DUAL V (P =.9043), and 44% and 25%, respectively, in DUAL VIII (P <.0001). Conclusions: IDegLira was associated with significantly greater increases in dTIR versus basal insulin alone in people with T2D. Trial ID(s): ClinicalTrials.gov, NCT01952145 (DUAL V); ClinicalTrials.gov,
KW - IDegLira
KW - insulin
KW - self-monitored blood glucose
KW - time in range
UR - http://www.scopus.com/inward/record.url?scp=85147432117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147432117&partnerID=8YFLogxK
U2 - 10.1177/19322968221149041
DO - 10.1177/19322968221149041
M3 - Article
C2 - 36710452
AN - SCOPUS:85147432117
SN - 1932-2968
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
ER -